slides · global inventory
Quote
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 18,554
Current window 1,261-1,290
Pages 619
Rows per page 30
Component
1,261-1,290 of 18,554
279
The slide uses highlighted quotes from a former senior medical affairs employee to undermine the commercial viability of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
286
The slide uses highlighted text to emphasize key concerns about cardiac risk, genetic subtypes, and the drug's unknown mechanism of action.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
294
The slide uses direct quotes from a KOL to undermine the company's narrative of drug efficacy and market adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
300
The slide uses a Q&A format to highlight specific quotes from a trial investigator regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
329
The slide uses a Q&A format to document expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
347
The slide uses a combination of summary text and verbatim Q&A transcripts to highlight negative sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
359
The slide uses direct quotes to undermine the credibility of the company's sales representatives and the drug's market reception.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
375
The slide uses highlighted text to emphasize key phrases from the expert's transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
391
The slide uses a 'quote-sandwich' technique: a summary paragraph followed by verbatim Q&A transcripts with highlighted key phrases.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
397
The slide uses direct quotes to build a case against the company's commercial execution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
406
The slide uses a Q&A format to highlight physician reluctance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 4 hits
03
The slide uses anecdotal evidence to frame the company's leadership as a 'villain' figure, specifically highlighting potential legal and regulatory scrutiny.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Testimonials from Industry Experts4 hits
17
The slide uses highly charged, aggressive language to frame the company and its leadership as predatory and unprofessional.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Critique of TransMedics Group Inc.4 hits
18
The slide uses direct quotes to build a narrative of customer churn risk, specifically highlighting the threat of switching to OrganOX.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Critique of TransMedics Group Inc.4 hits
24
The slide uses a 'villain' framing to attack the company's business model as exploitative of the US healthcare system.TransMedics (TMDX) · Scorpion Capital
Research note Short seller Beat · Exposure of Contradictions4 hits
58
The slide uses a combination of legal theory and qualitative expert testimony to build a case for anticompetitive behavior.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
103
The slide uses expert testimony to build a case for high customer concentration and potential ethical/business risks.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
205
The slide uses direct quotes from an organ procurement technician to build a case against NOP surgeons' technical proficiency.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
208
The slide uses a 'villain' narrative structure to cast doubt on the company's operational standards.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
251
The slide uses highlighted text to emphasize key grievances (dishonesty, forced bundling, anger).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
264
The slide uses a Q&A format to highlight a perceived cover-up by the company regarding device performance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
271
The slide uses direct quotes from surgeons to build a narrative of financial unviability and institutional pushback against the product.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
273
The slide uses direct quotes to build a narrative of customer churn and institutional resistance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
275
The slide uses a 'villain critique' style to highlight negative sentiment from industry insiders regarding TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
286
The slide uses a Q&A format to highlight the gap between the device's intended utility and real-world clinical experience.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
292
The slide uses highlighted text to emphasize key negative claims from a surgeon.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
293
The slide uses expert testimonials to argue that the TransMedics device is 'fatally flawed' because it does not allow for functional assessment under load.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
306
The slide uses a 'villain' narrative structure to frame TransMedics as vulnerable to upcoming competition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
307
The slide uses expert testimony to build a bearish case against the incumbent (TransMedics).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits
309
The slide uses direct quotes from an OrganOx employee and a leading transplant surgeon to validate the thesis.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 4 hits